These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9157479)

  • 1. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
    Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
    Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas.
    Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Lorenz WJ; Maier-Borst W; van Kaick G
    Eur J Nucl Med; 1995 May; 22(5):434-42. PubMed ID: 7641752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
    Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
    Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma.
    de Wit M; Bumann D; Beyer W; Herbst K; Clausen M; Hossfeld DK
    Ann Oncol; 1997; 8 Suppl 1():57-60. PubMed ID: 9187431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
    Kotzerke J; Guhlmann A; Moog F; Frickhofen N; Reske SN
    Eur J Nucl Med; 1999 Jan; 26(1):31-8. PubMed ID: 9933659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for detection and staging of malignant lymphoma.
    Buchmann I; Moog F; Schirrmeister H; Reske SN
    Recent Results Cancer Res; 2000; 156():78-89. PubMed ID: 10802866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of malignant lymphomas with F-18 FDG coincidence detection positron emission tomography.
    Hwang K; Park CH; Kim HC; Kim H; Yoon S; Pai M; Kim S
    Clin Nucl Med; 2000 Oct; 25(10):789-95. PubMed ID: 11043718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
    Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
    Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K
    Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
    Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
    J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
    Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
    J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of 18Fluorine-deoxyglucose (FDG) positron emission tomography in the management of lymphomas].
    Massardo V T; Canessa G J; Jofré M MJ; González E P; Humeres A P; Sierralta G P
    Rev Med Chil; 2006 Jul; 134(7):910-9. PubMed ID: 17130976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma].
    Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U
    Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C; Lépine M; Verreault J; Bénard F
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison].
    Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M
    Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.